Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-22-052756
Date:2022-10-03
Issuer: DAY ONE BIOPHARMACEUTICALS, INC. (DAWN)
Original Submission Date:

Reporting Person:

GRANT JULIE PAPANEK
2000 SIERRA POINT PARKWAY, SUITE 501
BRISBANE, CA 94080

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2022-10-03 S 5,000 d $20.06 434,358 indirect f3
COMMON STOCK 2022-10-04 S 5,000 d $20.00 429,358 indirect f3
COMMON STOCK 2022-10-03 0 $0.00 868 indirect f4
COMMON STOCK 2022-10-03 0 $0.00 6,964,301 indirect f5
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 the sales reported on this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person.
f2 the reported price in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $20.00 to $20.28 per share, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
f3 represents shares held by the grant family delaware trust agreement of which the reporting person is trustee. the reporting person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of section 16 of the securities exchange act of 1934, as amended (the "act"), or for any other purpose.
f4 represents shares held by the adam and julie grant revocable trust dtd october 13, 2017 of which the reporting person and her spouse are co-trustees. the reporting person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of section 16 of the act, or for any other purpose.
f5 represents shares held by canaan xi l.p. the reporting person is a non-managing member of canaan partners xi llc, the general partner of canaan xi l.p. the reporting person does not have voting or dispositive power over any of the shares held directly by canaan xi l.p. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of section 16 of the act, or for any other purpose.
WhaleWisdom Logo

Elevate your investments